Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26555ArticlesСтатьиResearch ArticleLechenie gormonorefrakternogo raka predstatel'noy zhelezy: rol' estratsitaЛечение гормонорефрактерного рака предстательной железы: роль эстрацитаRusakovI GРусаковИ ГAlekseevB YaАлексеевБ ЯМосковский научно-исследовательский онкологический институт им. П.А.Герцена1509200463VOL 6, NO3 (2004)ТОМ 6, №3 (2004)11612109042020Copyright ©; 2004, Consilium MedicumCopyright ©; 2004, ООО "Консилиум Медикум"2004Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26555

Рак предстательной железы (РПЖ) является в настоящее время одним из наиболее распространенных видов злокачественных новообразований в мире. Дальнейшее прогрессирование болезни приводит к потере чувствительности к андрогенным воздействиям, после чего развивается гормонорефрактерная стадия опухолевого процесса (гормонорефрактерный рак предстательной железы - ГРРПЖ). Средняя продолжительность жизни больных РПЖ на этом этапе не превышает 6-12 мес. Лечение ГРРПЖ является сложным и многоэтапным процессом. Эстрацит, сочетая в своем механизме действия цитостатический противоопухолевый эффект и гормональный эффект, с успехом может применяться на всех этапах терапии ГРРПЖ, общий объективный ответ на лечение составляет 40-50%. Благодаря незначительной миелосупрессивной токсичности и синергизму с различными противоопухолевыми агентами эстрамустин является базисным препаратом для проведения различных схем полихимиотерапии. Таким образом, терапия Эстрацитом и комбинированная терапия с его применением являются методами выбора лечения ГРРПЖ.

Ries L.A.G, Kosary C.L, Hankey B.F et al. (eds) SEER Cancer Statistics Review 1973-1995 Bethesda, MD: National Cancer Institute, 1998.Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002 Jul; 90(2):162-73.Чиссов В.И., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2002 году (заболеваемость и смертность). С.21-4.Huggins C, Hodges C.U. Studies on prostate cancer. I. The effect of castration? Of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293.Schellhammer P.F. Combined androgen blocade for the treatment of metastatic cancer of the prostate. Urology 1996; 47: 622-8.Gittes R. Carcinoma of the prostate. N Engl J Med 1991; 324: 236-45.Bruchovsky N, Lesser B, Van Doorn E et al. Hormonal effects on cell proliferation in rat prostate. Vitam. Horm. 1975; 33: 61-102.Isaacs J.T. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5: 545-57.Veldscholte J, Ris-Stalpers C, Kuiper G et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti - androgens. Biochem Biophis Res Commun 1990; 173: 534-40.Suzuki H, Sato N, Watabe Y et al. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46: 759-65.Sharief Y, Wilson E.M, Hall S.H et al. Androgen receptor gene mutations associated with prostatic carcinoma. Proc 86th AACR Meeting, Toronto, Ontario, Canada, 1995; 36: abstr. 1605.Tilley W.D, Buchanan G, Hickey T.E et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2: 227-85.Visacorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 1995; 9: 401-06.Culig Z, Hobisch A, Cronauer M.V et al. Androgen recettor activation in prostate tumor cell lines by insulin - like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-8.Nazareth I. V., Weigel N.L. Activation of the human androgen receptor throuth a protein kinase A signaling pathway. J Biol Chem 1996; 271: 19900-7.Fowler J.E, Whitmore W.F. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126: 372-5.Eisenberger M.A, Simon R, O’Dwyer P.J et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827-41.Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone - resistant prostate cancer. Cancer 1993; 71: 1098-109.Bubley G.J, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen - independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7.Andersson S.B, Gunnarsson P.O, Nilsson Tet al. Metabolism of estramustine phosphaye (Estracyt) in patients with prostatic carcinoma. Eur J Drug Metab Pharmacokinet 1981; 6: 149-54.Stearns M.E, Tew K.D. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res 1985; 45: 3891-7.Kajaer T.B, Nilsson T, Madsen P.O. Effect of estramustine phosphate on plasma testosterone during treatment of carcinoma of the prostate. Urology 1975; 5: 802-4.Jonsson G, Hodberg B. Treatment of advanced prostatic carcinoma with Estracyt. Scand J Urol Nephrol 1971; 5: 103-7.Hansenson M, Lundh B, Hartley-Asp B et al. Growth - inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r. Urol Res 1988; 16: 357-61.Benson R.C, Gill G.M. Estramustine phosphate compared with diethylstilbestrol. A randomized, double - blind, crossover trial for stage D cancer, Am J Clin Oncol 1986; 9: 341-51.Chisholm G.D, O’Donoghue E.P.N, Kennedy C.L. The treatment of oestrogen - escaped carcinoma of the prostate with estramustine phosphate. Br J Urol 1977; 49: 717-20.Jonsson G, Hodberg B, Nilsson T. Treatment of advanced prostatic carcinoma with estramustine phosphate. Scand J Urol Nephrol 1977; 11: 231-8.Kuss R, Khoury S, Richard F et al. Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 1980; 52: 29-33.Leistenschneider W, Nagel R. Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry. Eur Urol. 1980; 6: 11-115.Mittelman A, Shukla S.K, Murphy G.P. Extended therapy of stage D carcinoma of prostate with oral Estracyt. J Urol 1976; 115: 409-12.Takayasu H, Shida K, Momose S. et al. Clinical study on the treatment of prostatic carcinoma with Estracyt. Nishinihon J Urol 1982; 44: 889-99.Murphy G.P, Gibbons R.P, Johanson D.E et al. A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive radiation. J Urol 1977; 118: 288-91.Soloway M.S, de Kernion J.B, Gibbons R.P. et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory previously irradiated carcinoma of the prostate. J Urol 1981; 125: 664-7.Soloway M.S, Beckley S, Brady M.F et al. A comparison of estramustine phosphate versus cisplatinum alone versus estramustine phosphate plus cisplatinum in patients with advanced hormone refractory cancer who have had extensive irradiation to the pelvis or lumbosacral area. J Urol. 1983; 129: 56-61.Loening S.A, Beckly S, Brady M.F et al. Comparison of estramustine phosphate, methotrexate and cisplatinum in patients with advanced hormone refractory prostate cancer. J Urol 1983; 129: 1001-6.Newling D, Fossa S, Tunn U et al. Preliminary results of phase II study of mitomycin C versus estramustine in progressive metastatic prostate cancer refractory to hormone therapy - results of EORTC study group No. 30865. Abstr Eur J Cancer. 1990; 26: 152.Kreis W, Budman D.R, Calabro A. Unique synergism or antagonism of chemotherapeutic and horal agents in human prostate cancer cell lines. Br J Urol. 1997; 79: 196-202.Hudes G.R, Roth B.J, Loehrer H. Phase III trial of vinblstine versus vinblastine plus estramustine phosphate for metastatic hormone - refractory prostate cancer. Proc Am Soc Clin Oncol. 1997; 16: 1127.Smith D.C, Esper P, Strawderman M et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone - refractory prostate cancer. J Clin Oncol. 1999; 17: 1664-71.Hudes G.R, Nathan F, Khater C et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone - refractory prostate cancer. J Clin Oncol. 1997; 15: 3156-63.Petrylak D.P, Macarthur R.B, O’Connor J et al. Phase I trial of docetaxel with estramustine in androgen - independent prostate cancer. J Clin Oncol. 1999; 17: 958-67.Pienta K.J, Redman B.G, Hussain M et al. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate/ J Clin Oncol. 1994; 12: 2005-12.Pienta K.J, Redman B.G, Bandekar R et al. A phase II trial of oral etoposide in hormonal refractory prostate cancer. Urology. 1997; 50: 401-6.Dimopoulos M.A, Panopoulos C, Bamia C et al. Oral estramustine and oral etoposide for hormone - refractory prostate cancer. Urology 1997; 50: 754-8.Natale R, Zaretsky S. Phase I/II trial of estramustine and taxotere in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999; 1343.Savarese D, Taplin M.E, Halabi S et al. A phase II study of docetaxel (Taxotere), estramustine and low - dose hydrocortisone in men with hormone refractory prostate cancer: preliminary resultsof cancer and leukemia group B Trial 9780. Semin Oncol 1999; 26: 39-44.Kreis W, Budman D.R, Fetten J et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999; 10: 33-8.Hedlung P.O. Estracyt - mode of action and clinical experience. Prog Clin Biol Res 1987; 243B: 215-19.Ando M, Tamayose K, Sugimoto K et al. Secondary myelodysplastic syndrome after treatment of prostate cancer with oral estramustine. Am J Hematol 2001; 67: 274-5.